Food and Drug Regulations (C.R.C., c. 870)

Salicylates

• C.09.030 (1) The adult standard dosage unit of a salicylate shall be

  • (a) in the case of acetylsalicylic acid, sodium salicylate and magnesium salicylate, 325 mg; and

  • (b) in the case of choline salicylate, 435 mg.

• (2) The children’s standard dosage unit of a salicylate shall be

  • (a) in the case of acetylsalicylic acid, sodium salicylate and magnesium salicylate, 80 mg; and

  • (b) in the case of choline salicylate, 110 mg.

• C.09.031 (1) In this Division, salicylate product means a drug that contains

  • (a) a salt or derivative of salicylic acid as a single medicinal ingredient;

  • (b) a salt or derivative of salicylic acid in combination with caffeine;

  • (c) a salt or derivative of salicylic acid in combination with one or more buffering agents or antacids; or

  • (d) a salt or derivative of salicylic acid in combination with caffeine and one or more buffering agents or antacids.

• (2) No manufacturer or importer shall sell a salicylate product after June 30, 1986 unless it meets the requirements of this Division.

• (3) No manufacturer or importer shall, until June 30, 1986, sell a salicylate product in a dosage unit other than one mentioned in this Division, unless the salicylate product was legally available for sale in Canada on February 1, 1984.

• C.09.032 (1) Subject to subsections (2) and (3) and section C.09.035, a salicylate product in the form of a tablet, capsule or other solid dosage form intended for oral administration shall contain one adult standard dosage unit of a salicylate per individual dosage form.

• (2) A salicylate product in the form of a tablet, capsule or other solid dosage form intended for oral administration may contain

  • (a) 500 mg of acetylsalicylic acid, sodium salicylate or magnesium salicylate, or

  • (b) 670 mg of choline salicylate

  per individual dosage form if it has a label that states that it is not a standard dosage unit product.

• (3) A salicylate product in the form of a tablet, capsule or other solid dosage form intended for oral administration may contain

  • (a) two adult standard dosage units of a salicylate per individual dosage form if the label of the salicylate product states that each individual dosage form contains two adult standard dosage units; and

  • (b) three adult standard dosage units of a salicylate per individual dosage form if the label of the salicylate product states that each individual dosage form contains three adult standard dosage units.

• C.09.033 (1) Subject to subsection (2), a salicylate product in the form of a liquid shall contain one adult standard dosage unit of a salicylate per teaspoon.

• (2) A salicylate product in the form of a liquid may contain

  • (a) two adult standard dosage units of a salicylate per teaspoon if the label of the salicylate product states that each teaspoon of the product contains two adult standard dosage units; and

  • (b) three adult standard dosage units of a salicylate per teaspoon if the label of the salicylate product states that each teaspoon of the product contains three adult standard dosage units.

C.09.034 A salicylate product that is claimed to be buffered shall provide at least 1.9 milliequivalents of acid neutralizing capacity per adult standard dosage unit of a salicylate.

C.09.035 A salicylate product in the form of a tablet, capsule or other solid dosage form intended for oral administration and that is specially recommended for children shall contain one children’s standard dosage unit of a salicylate per individual dosage form.

DIVISION 10Access to Drugs in Exceptional Circumstances

• C.10.001 (1) The following definitions apply in this section.

  foreign regulatory authority

  foreign regulatory authority means a government agency or other entity outside Canada that has a legal right to control the manufacturing, use or sale of drugs within its jurisdiction. (autorité réglementaire étrangère)

  public health official

  public health official means

  • (a) the Chief Public Health Officer appointed under subsection 6(1) of the Public Health Agency of Canada Act;

  • (b) the Chief Medical Officer of Health, or equivalent, of a province;

  • (c) the Surgeon General of the Canadian Armed Forces; or

  • (d) the Chief Medical Officer of Public Health for the First Nations and Inuit Health Branch of the Department of Health. (responsable de la santé publique)

• (2) Despite sections A.01.040 and C.01.004.1, any person who holds an establishment licence that authorizes the importation of a drug may import a drug for which a notice of compliance has not been issued under section C.08.004 or C.08.004.01, or for which a drug identification number has not been assigned under subsection C.01.014.2(1), if the following conditions are met:

  • (a) a public health official has, within the past year, notified the Minister in writing of

    • (i) an urgent public health need for the immediate use of the drug within their jurisdiction, and

    • (ii) the intended use or purpose of the drug;

  • (b) the drug is authorized by a foreign regulatory authority in the United States, Switzerland or the European Union to be sold for the same use or purpose as that described under subparagraph (a)(ii);

  • (c) the drug is in the same category as the category for which the licence was issued;

  • (d) the drug is imported directly from the country in which it is authorized to be sold by the foreign regulatory authority; and

  • (e) the drug is one for which the following information is set out in the List of Drugs for an Urgent Public Health Need that is published by the Government of Canada on its website, as amended from time to time:

    • (i) brand name,

    • (ii) medicinal ingredients,

    • (iii) dosage form,

    • (iv) strength,

    • (v) route of administration, and

    • (vi) identifying code or number, if any, assigned in the country in which the drug was authorized for sale.

• (3) Sections C.01A.006 and C.01A.007 do not apply in respect of the importation of a drug under subsection (2).

• (4) For greater certainty, a licensee may, despite subsection C.01A.004(1), import a drug under subsection (2) without having their licence amended under section C.01A.006.

• (5) Divisions 2 to 4, other than the following provisions, do not apply to the importation of a drug under subsection (2):

  • (a) sections C.02.003.1 and C.02.004 as they apply to the storage of the drug by the licensee;

  • (b) section C.02.006;

  • (c) subsection C.02.012(1);

  • (d) sections C.02.013 and C.02.014;

  • (e) section C.02.015 as it applies to the storage and transportation of the drug by the licensee;

  • (f) subsection C.02.021(1) as it applies to the storage of the drug by the licensee;

  • (g) subsection C.02.022(1);

  • (h) section C.02.023;

  • (i) subsections C.02.024(1) and C.02.025(1);

  • (j) section C.03.013; and

  • (k) section C.04.001.1 as it applies to the storage of the drug by the licensee.